Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.47 |
| ▸ | F2 | P00734 | 6/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.46 |
| ▸ | PROC | P04070 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361685 | 0.89 | F10 (0.49) | F10F2KLKB1PROCPRSS1 | |
| SCHEMBL3473045 | 0.86 | HDAC3 (0.50) | — | |
| SCHEMBL2261340 | 0.81 | TP53 (0.46) | F10F2KLKB1 | |
| SCHEMBL2260222 | 0.81 | NPY5R (0.53) | F10F2KLKB1PROCPRSS1 | |
| SCHEMBL2256555 | 0.81 | CARM1 (0.55) | CARM1 | |
| SCHEMBL12361694 | 0.80 | F10 (0.47) | F10F2KLKB1PROCPRSS1 | |
| SCHEMBL2261781 | 0.79 | IGF1R (0.46) | F10F2KLKB1CARM1 | |
| SCHEMBL6783789 | 0.79 | KLKB1 (0.48) | F10F2KLKB1PROCPRSS1 | |
| SCHEMBL2259914 | 0.78 | NPY5R (0.52) | F10F2KLKB1PROCPRSS1 | |
| SCHEMBL6712376 | 0.78 | MAPK14 (0.45) | F10F2KLKB1PROCPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | F10 143/4885F2 290/4885KLKB1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.